Skip to main content

Advertisement

SpringerLink
Log in

A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis

  • Original Article
  • Published:
Cell Biology and Toxicology Aims and scope Submit manuscript

Abstract

Purpose

The 26S proteasome plays important roles in many intracellular processes and is therefore a critical intracellular cellular target for anticancer treatments. The primary aim of the current study was to identify critical proteins that may play roles in opposing the antisurvival effect of the proteasome inhibitor bortezomib together with the calcium-chelator BAPTA-AM in cancer cells using label-free LC-MS/MS. In addition, based on the results of the proteomic technique, a novel and more effective inhibitor combination involving bortezomib as well as OTSSP167 was developed for breast cancer cells.

Methods and results

Using label-free LC-MS/MS, it was found that expressions of 1266 proteins were significantly changed between the experimental groups. Among these proteins were cell division cycle 5-like (Cdc5L) and drebrin-like (DBNL). We then hypothesized that inhibition of the activities of these two proteins may lead to more effective anticancer inhibitor combinations in the presence of proteasomal inhibition. In fact, as presented in the current study, Cdc5L phosphorylation inhibitor CVT-313 and DBNL phosphorylation inhibitor OTSSP167 were highly cytotoxic in 4T1 breast cancer cells and their IC50 values were 20.1 and 43 nM, respectively. Under the same experimental conditions, the IC50 value of BAPTA-AM was found 19.9 μM. Using WST 1 cytotoxicity assay, it was determined that 10 nM bortezomib + 10 nM CVT-313 was more effective than the control, the single treatments, or than 5 nM bortezomib + 5 nM CVT-313. Similarly, 10 nM bortezomib + 10 nM OTSSP167 was more cytotoxic than the control, the monotherapies, 5 nM bortezomib + 5 nM OTSSP167, or than 5 nM bortezomib + 10 nM OTSSP167, indicating that bortezomib + OTSSP167 was also more effective than bortezomib + CVT-313 in a dose-dependent manner. Furthermore, the 3D spheroid model proved that bortezomib + OTSSP167 was more effective than the monotherapies as well as bortezomib + CVT-313 and bortezomib + BAPTA-AM combinations. Finally, the effect of bortezomib + OTSSP167 combination was tested on MDA-MB-231 breast cancer cells, and it similarly determined that 20 nM bortezomib +40 nM OTSSP167 combination completely blocked the formation of 3D spheroids.

Conclusions

Altogether, the results presented here indicate that bortezomib + OTSSP167 is a novel and effective combination and may be tested further for cancer treatment in vivo and in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9–16.

    Article  CAS  PubMed  Google Scholar 

  • Aras B, Yerlikaya A. Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. Oncol Lett. 2016;11:3179–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bayram D, Çetin ES, Kara M, Özgöçmen M, Candan IA. The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells. Hum Exp Toxicol. 2017;36:573–86.

    Article  CAS  PubMed  Google Scholar 

  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

    Article  CAS  Google Scholar 

  • Chan EY, Sutton JN, Jacobs JM, Bondarenko A, Smith RD, Katze MG. Dynamic host energetics and cytoskeletal proteomes in human immunodeficiency virus type 1-infected human primary CD4 cells: analysis by multiplexed label-free mass spectrometry. J Virol. 2009;83:9283–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chao A, Wang TH. Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors. Taiwan J Obstet Gynecol. 2016;55:3–8.

    Article  PubMed  Google Scholar 

  • Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005;65:5599–606.

    Article  CAS  PubMed  Google Scholar 

  • Chen LY, Chiang AS, Hung JJ, Hung HI, Lai YK. Thapsigargin-induced grp78 expression is mediated by the increase of cytosolic free calcium in 91 rat brain tumor cells. J Cell Biochem. 2000;78:404–16.

    Article  CAS  PubMed  Google Scholar 

  • Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2010;21:864–70.

    Article  CAS  PubMed  Google Scholar 

  • Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012;3:1629–40.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ding X, Matsuo K, Xu L, Yang J, Zheng L. Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer. Anti-Cancer Drugs. 2015;26:547–54.

    Article  CAS  PubMed  Google Scholar 

  • Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012;1825:64–76.

    CAS  PubMed  Google Scholar 

  • Freshney RI. Cytotoxicity, in culture culture of animal cells: a manual of basic technique. 5th ed. Hoboken: Wiley; 2005. p. 359.

    Book  Google Scholar 

  • Gräub R, Lancero H, Pedersen A, Chu M, Padmanabhan K, Xu X-Q, et al. Cell cycle-dependent phosphorylation of human CDC5 regulates RNA processing. Cell Cycle. 2008;7:1795–803.

    Article  PubMed  PubMed Central  Google Scholar 

  • Guarguaglini G, Duncan PI, Stierhof YD, Holmström T, Duensing S, Nigg EA. The forkhead-associated domain protein Cep170 interacts with polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell. 2005;16:1095–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hambley B, Caimi PF, William BM. Bortezomib for the treatment of mantle cell lymphoma: an update. Ther Adv Hematol. 2016;7:196–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hendershot LM. The ER function BiP is a master regulator of ER function. Mt Sinai J Med. 2004;71:289–97.

    PubMed  Google Scholar 

  • Jakobi R, McCarthy CC, Koeppel MA, Stringer DK. Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. J Biol Chem. 2003;278:38675–85.

    Article  CAS  PubMed  Google Scholar 

  • Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–13.

    Article  PubMed  Google Scholar 

  • Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–4.

    Article  CAS  PubMed  Google Scholar 

  • Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008;26:2320–6.

    Article  CAS  PubMed  Google Scholar 

  • Li B, Cheng XL, Yang YP, Li ZQ. GRP78 mediates radiation resistance of a stem cell-like subpopulation within the MCF-7 breast cancer cell line. Oncol Rep. 2013;30:2119–26.

    Article  CAS  PubMed  Google Scholar 

  • Li Z, Park HR, Shi Z, Li Z, Pham CD, Du Y, et al. Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. Oncotarget. 2014;5:3197–209.

    PubMed  PubMed Central  Google Scholar 

  • Löffek S, Wöll S, Höhfeld J, Leube RE, Has C, Bruckner-Tuderman L, et al. The ubiquitin ligase CHIP/STUB1 targets mutant keratins for degradation. Hum Mutat. 2010;31:466–76.

    Article  CAS  PubMed  Google Scholar 

  • Lundberg KC, Fritz Y, Johnston A, Foster AM, Baliwag J, Gudjonsson JE, et al. Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans. Mol Cell Proteomics. 2015;14:109–19.

    Article  CAS  PubMed  Google Scholar 

  • Neubert H, Bonnert TP, Rumpel K, Hunt BT, Henle ES, James IT. Label-free detection of differential protein expression by LC/MALDI mass spectrometry. J Proteome Res. 2008;7:2270–9.

    Article  CAS  PubMed  Google Scholar 

  • Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649–57.

    Article  CAS  PubMed  Google Scholar 

  • Qiu H, Zhang X, Ni W, Shi W, Fan H, Xu J, et al. Expression and clinical role of Cdc5L as a novel cell cycle protein in hepatocellular carcinoma. Dig Dis Sci. 2016a;61:795–805.

    Article  CAS  PubMed  Google Scholar 

  • Qiu H, Zhang X, Ni W, Shi W, Fan H, Xu J, et al. Expression and clinical role of Cdc5L as a novel cell cycle protein in hepatocellular carcinoma. Dig Dis Sci. 2016b;61:795–805.

    Article  CAS  PubMed  Google Scholar 

  • Schlatzer DM, Sugalski J, Dazard JE, Chance MR, Anthony DD. A quantitative proteomic approach for detecting protein profiles of activated human myeloid dendritic cells. J Immunol Methods. 2012;375:39–45.

    Article  CAS  PubMed  Google Scholar 

  • Shimada Y, Nishimura E, Hoshina H, Kobayashi H, Higuchi T, Eto Y, et al. Proteasome inhibitor bortezomib enhances the activity of multiple mutant forms of lysosomal α-glucosidase in pompe disease. JIMD Rep. 2015;18:33–9.

    Article  PubMed  Google Scholar 

  • Sirenko O, Mitlo T, Hesley J, Luke S, Owens W, Cromwell EF. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Assay Drug Dev Technol. 2015;13:402–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tomechko SE, Liu G, Tao M, Schlatzer D, Powell CT, Gupta S, et al. Tissue specific dysregulated protein subnetworks in type 2 diabetic bladder urothelium and detrusor muscle. Mol Cell Proteomics. 2015;14:635–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H, Song X, Logsdon C, Zhou G, Evans DB, Abbruzzese JL, et al. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res. 2009;69:1063–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.

    Article  CAS  PubMed  Google Scholar 

  • Yerlikaya A, Erin N. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor velcade. Int J Mol Med. 2008;22:817–23.

    CAS  PubMed  Google Scholar 

  • Yerlikaya A, Yöntem M. The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov. 2013;8:298–309.

    Article  CAS  PubMed  Google Scholar 

  • Yerlikaya A, Erdoğan E, Okur E, Yerlikaya Ş, Savran B. A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncol Lett. 2016;12:323–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang Y, Tseng CC, Tsai YL, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One. 2013;8:e80071.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported in part by Scientific and Research Council of Turkey (Grant No. 113S400).

Author information

Authors and Affiliations

  1. Art and Science Faculty, Department of Biology, Kütahya Dumlupınar University, Kütahya, Turkey

    Emrah Okur

  2. Faculty of Medicine, Department of Medical Biology, Kütahya Health Sciences University, Kütahya, Turkey

    Azmi Yerlikaya

Authors
  1. Emrah Okur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azmi Yerlikaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Azmi Yerlikaya.

Ethics declarations

Conflicts of interest

All authors declare that they have no conflicts of interest.

Electronic supplementary material

Supplemental Figure 1

Graphical presentation of selected proteins significantly upregulated in response to bortezomib + BAPTA-AM. The expression level of were identified by label-free LC-MS/MS. Con, control; Bor, 10 nM bortezomib; BAPTA, 5 μM BAPTA-AM. (DOCX 242 kb)

Supplemental Table 1

Significantly upregulated or downregulated proteins in response to bortezomib + BAPTA-AM. The analyzes were carried out by label-free LC-MS/MS. (XLSX 227 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okur, E., Yerlikaya, A. A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis. Cell Biol Toxicol 35, 33–47 (2019). https://doi.org/10.1007/s10565-018-9435-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10565-018-9435-z

Keywords

Search

Navigation